Literature DB >> 17720359

Cardiovascular and metabolic risk factors: how can we improve outcomes in the high-risk patient?

Scott M Grundy1.   

Abstract

Risk assessment algorithms, such as that used in the third Adult Treatment Panel (ATP III) of the National Cholesterol Education Program (NCEP) for treating low-density lipoprotein cholesterol, can be used to classify patients' risk for cardiovascular and metabolic problems and to determine the appropriate level of therapeutic intervention. Patients at highest risk should receive the most intensive therapy. The presence of the metabolic syndrome, a clustering of atherogenic risk factors including dyslipidemia, elevated blood pressure, elevated blood glucose, and other problems, confers additional risk for diabetes mellitus and atherosclerotic cardiovascular disease at every level of risk. Pharmacotherapy with lipid-lowering, antiplatelet, antihypertensive, or insulin-sensitizing agents to modify specific risk factors is indicated in patients at higher risk, but lifestyle change (e.g., smoking cessation, weight reduction, increased physical activity, and "heart-healthy" dietary modifications) and blood pressure control can be used across all categories of risk.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17720359     DOI: 10.1016/j.amjmed.2007.06.005

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  14 in total

Review 1.  The role of statins in the treatment of the metabolic syndrome.

Authors:  Christian Ott; Roland E Schmieder
Journal:  Curr Hypertens Rep       Date:  2009-04       Impact factor: 5.369

2.  Efficacy of lifestyle interventions in physical health management of patients with severe mental illness.

Authors:  Fernando Chacón; Fernando Mora; Alicia Gervás-Ríos; Inmaculada Gilaberte
Journal:  Ann Gen Psychiatry       Date:  2011-09-19       Impact factor: 3.455

Review 3.  Weight control and prevention of metabolic syndrome by green tea.

Authors:  Sudathip Sae-tan; Kimberly A Grove; Joshua D Lambert
Journal:  Pharmacol Res       Date:  2010-12-28       Impact factor: 7.658

Review 4.  Metabolic syndrome and hepatic resection: improving outcome.

Authors:  Shefali Agrawal; Cherag Daruwala
Journal:  HPB (Oxford)       Date:  2011-10-19       Impact factor: 3.647

5.  Agreement Between Results of Home Sleep Testing for Obstructive Sleep Apnea with and Without a Sleep Specialist.

Authors:  R Nisha Aurora; Nirupama Putcha; Rachel Swartz; Naresh M Punjabi
Journal:  Am J Med       Date:  2016-03-08       Impact factor: 4.965

6.  Genetic variations of HSPA1A, the heat shock protein levels, and risk of atherosclerosis.

Authors:  Elena Dulin; Pedro García-Barreno; Maria C Guisasola
Journal:  Cell Stress Chaperones       Date:  2012-02-11       Impact factor: 3.667

7.  Selecting data elements to build a patient-centric electronic health record that will support adherence to therapeutic lifestyle change.

Authors:  Connie Chan; Alwyn Cohall; David Kaufman; Sharib Khan; Rita Kukafka
Journal:  AMIA Annu Symp Proc       Date:  2008-11-06

8.  Fatty acid- and cholesterol transporter protein expression along the human intestinal tract.

Authors:  Christiaan J Masson; Jogchum Plat; Ronald P Mensink; Andrzej Namiot; Wojciech Kisielewski; Zbigniew Namiot; Joachim Füllekrug; Robert Ehehalt; Jan F C Glatz; Maurice M A L Pelsers
Journal:  PLoS One       Date:  2010-04-29       Impact factor: 3.240

9.  Weight loss in individuals with metabolic syndrome given DASH diet counseling when provided a low sodium vegetable juice: a randomized controlled trial.

Authors:  Sonia F Shenoy; Walker Sc Poston; Rebecca S Reeves; Alexandra G Kazaks; Roberta R Holt; Carl L Keen; Hsin Ju Chen; C Keith Haddock; Barbara L Winters; Chor San H Khoo; John P Foreyt
Journal:  Nutr J       Date:  2010-02-23       Impact factor: 3.271

10.  Serum amyloid A impairs the antiinflammatory properties of HDL.

Authors:  Chang Yeop Han; Chongren Tang; Myriam E Guevara; Hao Wei; Tomasz Wietecha; Baohai Shao; Savitha Subramanian; Mohamed Omer; Shari Wang; Kevin D O'Brien; Santica M Marcovina; Thomas N Wight; Tomas Vaisar; Maria C de Beer; Frederick C de Beer; William R Osborne; Keith B Elkon; Alan Chait
Journal:  J Clin Invest       Date:  2015-12-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.